



FFW


FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

DAVID L. PARKER
PARTNER
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

June 30, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
June 30, 2004	
Date	David L. Parker

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/676,725 entitled "NOVEL ANTIBODY DELIVERY SYSTEM FOR BIOLOGICAL RESPONSE MODIFIERS" – Michael Rosenblum*
Our reference: CLFR:029USD1
Client reference: D-5033

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement and Form PTO-1449.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CLFR:029USD1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



David L. Parker
Reg. No. 32,165

DLP/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Michael Rosenblum

Serial No.: 10/676,725


Filed: October 1, 2003

For: NOVEL ANTIBODY DELIVERY
SYSTEM FOR BIOLOGICAL RESPONSE
MODIFIERS

Group Art Unit: 1615

Examiner: Unknown

Atty. Dkt. No.: CLFR:029USD1

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
June 30, 2004	
Date	David L. Parker

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be


an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CLFR:029USD1.

This application is a divisional application of Serial No. 07/348,237, filed May 5, 1989; Serial No. 07/951,357, filed September 25, 1992; Serial No. 08/119,505, filed September 10, 1993; and Serial No. 08/251,574, filed May 31, 1994 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) copies of the listed documents are not enclosed as they have been previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 07/348,237.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



David L. Parker
Reg. No. 32,165
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 30, 2004

Form PTO-1449 (modified)

Atty. Docket No.

CLFR:029USD1

Serial No.

10/676,725

List of Patents and Publications for Applicant's

Applicant

Michael Rosenblum

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 1, 2003

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,032,521	7/16/91	White <i>et al.</i>	530	388.85	3/23/87
	A2	4,650,674	3/17/87	Aggerwal <i>et al.</i>	424	85.5	12/03/84
	A3	4,671,958	6/09/87	Rodwell	424	130.1	
	A4	4,753,894	6/28/88	Frank <i>et al.</i>	435	7.23	1/11/85
	A5	4,771,128	9/13/88	Ferris <i>et al.</i>	530	391.7	10/10/86
	A6	4,870,163	9/26/89	Rubin <i>et al.</i>	530	413	8/29/85
	A7	4,935,233	6/19/90	Kell <i>et al.</i>	424	85.5	12/02/85

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	0184369	06/86	Europe			
	B2	0226418	12/85	Europe			
	B3	1564666	04/80	Great Britain			
	B4	EP 256714	2/24/88	Europe			
	B5	EP 281070	9/07/88	Europe			
	B6	WO 88/09344	12/01/88	PCT			
	B7	WO 89/06692	7/27/89	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Aggarwal and Kohr, <i>Methods in Enzymology</i> , 116:448-456, 1986.
	C2	Bradford, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding," <i>Analy. Biochem.</i> , 72:248-254, 1976.

25385564.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C3	Cotton <i>et al.</i> , <i>Eur. J. Immunol.</i> , 3:135-140, 1978.
	C4	Flannery <i>et al.</i> , "Immunomodulation: NK cells activated by interferon-conjugated monoclonal antibody against human osteosarcoma," <i>Exp. J. Cancer Clin. Oncol.</i> , 20(6):791-798, 1984.
	C5	Neville and Youle, Monoclonal antibody-ricin or ricin A chain hybrids: kinetic analysis of cell killing for tumor therapy," <i>Immunol. Rev.</i> , 62:75-91, 1982.
	C6	Pelham <i>et al.</i> , "Interferon- α conjugation to human osteogenic sarcoma monoclonal antibody 791T/36," <i>Cancer Immunol. Immunother.</i> , 15:210-216, 1983.
	C7	Raso <i>et al.</i> , "Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen," <i>Cancer Res.</i> , 42:457-464, 1982.
	C8	Rosenblum <i>et al.</i> , "Tumor necrosis factor: a multifaceted peptide hormone, <i>Critical Reviews in Immunology</i> , 21-44, 1989.
	C9	Ross <i>et al.</i> , "Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte)globulin or its F(ab') ₂ fragment," <i>Eur. J. Biochem.</i> , 104:381-390, 1980.
	C10	Schultz <i>et al.</i> , "Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo," <i>Proc. Natl. Acad. Sci., USA</i> , 80:5407-5411, 1983.
	C11	Shoemaker <i>et al.</i> , "Development of human tumor cell line panels for use in disease-oriented drug screening," In: <i>Prediction of Response Cancer Therapy</i> , 265-286, 1988.
	C12	Soule <i>et al.</i> , <i>JNCI</i> , 51(5):1409-141, 1978.
	C13	Trowbridge and Domingo, "Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells," <i>Nature</i> , 294:171-173, 1981.
	C14	Vitetta <i>et al.</i> , "Neoplastic B cells as targets for antibody-ricin A chain immunotoxins," <i>Immunol. Rev.</i> , 62:159-183, 1982.
	C15	Vogel <i>et al.</i> , "In vivo studies with covalent sonjugates of cobra venom factor and monoclonal antibodies to human tumors," <i>Haematology and Blood Transfusion</i> , 29:514-517, 1989.
	C16	White <i>et al.</i> , "Two monoclonal antibodies selective for human mammary carcinoma," <i>Cancer Res.</i> , 45(3):1337-1343, 1985.

25385564.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C17	Wilson <i>et al.</i> , "Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies," <i>Int. J. Cancer</i> , 28:293-300, 1981.

25385564.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.